NCT lookup

Inclusion Criteria:

* ≥ 16 years of age at the time of obtaining informed consent
* Eastern Cooperative Oncology Group performance status of 0 or 1 at screening
* At least one positron emission tomography (PET)-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy.
* Confirmed histological diagnosis of active relapse/refractory cHL
* Failed at least 2 prior lines of systemic therapy.
* No previous treatment with anti-TIM-3.
* Adequate organ and bone marrow function
* Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
* Minimum body weight ≥ 40 kg for all participants.

Exclusion Criteria:

* Unresolved toxicities of ≥ Grade 2 from prior therapy
* Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy
* Patients with central nervous system (CNS) involvement or leptomeningeal disease.
* History of allogeneic stem cell transplant or organ transplantation.
* Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
* Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
* History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
* Uncontrolled intercurrent illness.
* Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.
* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
* Other invasive malignancy within 2 years prior to screening
* Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention
* Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.

• Duarte, California, United States
• Miami, Florida, United States
• Rochester, Minnesota, United States
• New York, New York, United States
• Houston, Texas, United States
• Toronto, Ontario, Canada
• Montreal, Quebec, Canada
• København Ø, Denmark
• Lille, France
• Bologna, Italy
• Naples, Italy
• Valencia, Spain
• Manchester, United Kingdom
• Oxford, United Kingdom